Fibronectin Antibody - BSA Free

Western Blot: Fibronectin Antibody - BSA Free [NBP1-91258] - Nicotinamide (NAM) attenuates unilateral urethral obstruction (UUO)-induced renal interstitial fibrosis. C57BL/6 mice were subjected to UUO surgery or sham operation. Different doses of NAM or saline were intraperitoneally injected an hour before the surgery and daily thereafter. Representative images of Western blot of FN (fibronectin), alpha-SMA (alpha-smooth muscle actin) and GAPDH (loading control). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30993884/) licensed under a CC-BY license.

Western Blot: Fibronectin AntibodyBSA Free [NBP1-91258]

Western Blot: Fibronectin Antibody - BSA Free [NBP1-91258] - Analysis of Fibronectin in HepG2 cell lysate.

Western Blot: Fibronectin AntibodyBSA Free [NBP1-91258]

Western Blot: Fibronectin Antibody - BSA Free [NBP1-91258] - Analysis of Fibronectin in NIH 3T3 cell lysate.

Immunocytochemistry/ Immunofluorescence: Fibronectin Antibody - BSA Free [NBP1-91258]

Immunocytochemistry/Immunofluorescence: Fibronectin Antibody - BSA Free [NBP1-91258] - Fibronectin antibody was tested in HeLa cells with DyLight 488 (Green). Nuclei and alpha-tubulin were counterstained with DAPI (Blue) and DyLight 550 (Red).

Immunocytochemistry/ Immunofluorescence: Fibronectin Antibody - BSA Free [NBP1-91258]

Immunocytochemistry/Immunofluorescence: Fibronectin Antibody - BSA Free [NBP1-91258] - NIH-3T3 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-Fibronectin at 2 ug/mL overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at 1:500. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at 1:1000 and detected with an anti-mouse DyLight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Immunohistochemistry: Fibronectin Antibody - BSA Free [NBP1-91258]

Immunohistochemistry: Fibronectin Antibody - BSA Free [NBP1-91258] - Analysis of Fibronectin in human renal cancer using DAB with hematoxylin counterstain.

Immunohistochemistry-Paraffin: Fibronectin Antibody - BSA Free [NBP1-91258]

Immunohistochemistry-Paraffin: Fibronectin Antibody - BSA Free [NBP1-91258] - Analysis of Fibronectin in mouse kidney tissue section using anti-Fibronectin antibody. Image from verified customer review.

Immunohistochemistry-Paraffin: Fibronectin Antibody - BSA Free [NBP1-91258]

Immunohistochemistry-Paraffin: Fibronectin Antibody - BSA Free [NBP1-91258] - Analysis of Fibronectin in human oesophageal cancer tissue using anti-Fibronectin antibody. Image from verified customer review.

Immunohistochemistry-Frozen: Fibronectin Antibody - BSA Free [NBP1-91258]

Immunohistochemistry-Frozen: Fibronectin Antibody - BSA Free [NBP1-91258] - Feline corneal stromal cells. IHC-Fr and IF (Alexa Fluor488) were performed using NBP1-91258 at 1:400. Image captured by epifluorescent microscopy. Image from verified customer review.

Immunohistochemistry-Frozen: Fibronectin Antibody - BSA Free [NBP1-91258]

Immunohistochemistry-Frozen: Fibronectin Antibody - BSA Free [NBP1-91258] - Trabecular meshwork (TM) region of pig eyes. NBP1-91258 Fibronectin antibody was labelled with Alexa Fluor 488 conjugated secondary antibody (Green). DAPI shown as blue. Image from verified customer review.

Immunohistochemistry-Frozen: Fibronectin Antibody - BSA Free [NBP1-91258]

Immunohistochemistry-Frozen: Fibronectin Antibody - BSA Free [NBP1-91258] - Mouse brain cryosections were stained with Fibronectin and anti-rabbit Alexa Fluor 555. Magnification 20x. Image from vrified customer review.

Immunohistochemistry-Frozen: Fibronectin Antibody - BSA Free [NBP1-91258]

Immunohistochemistry-Frozen: Fibronectin Antibody - BSA Free [NBP1-91258] - Staining in mouse carotid artery. Image from a verified customer review.

Simple Western: Fibronectin AntibodyBSA Free [NBP1-91258]

Simple Western: Fibronectin Antibody - BSA Free [NBP1-91258] - Lane view shows a specific band for Fibronectin in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

Western Blot: Fibronectin Antibody - BSA Free [NBP1-91258] -

Western blot analysis of the effects of IP6, Ins, IP6 + Ins & normal saline on the levels of collagen IV, Lamininand Fibronectin. IP6 or Ins treatment decreased the protein expression of collagen IV, LN & FN, & the combined IP6 + Ins treatment resulted in significantly greater effects compared with treatment with either compound alone. The samples were probed with antibodies against p-collagen IV, p-LN, & p-FN. The Western blot membranes were stripped & reprobed for beta-actin as an internal control to confirm equal loading. (A) representative blots from one of three separate experiments; (B) relative band intensities based on densitometry. The results are expressed as the mean ± standard deviation from three independent experiments. * p < 0.05 compared to the IP6 + Ins group; #p < 0.05 compared to the normal saline group. Image collected & cropped by CiteAb from the following publication (http://www.mdpi.com/2072-6643/8/5/286), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Fibronectin Antibody - BSA Free [NBP1-91258] -

Immunocytochemistry/ Immunofluorescence: Fibronectin Antibody - BSA Free [NBP1-91258] - LC depressed both the protein & mRNA level of fibronectin via depletion of peritoneal M2. Values were expressed as the mean ± SD. (A) The overexpression of fibronectin induced by Lactate-4.25% dialysate was evidently downregulated by LC treatment measured by Western blotting; (B) The relative protein level of fibronectin normalized by GAPDH; (C) The mRNA level of fibronectin was depressed by LC treatment; (D) Immunofluorescence staining of fibronectin in the four groups. Blue corresponds to nuclear staining, & red corresponds to fibronectin staining. #p < 0.05 vs. NC & LC group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/23685870), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Fibronectin Antibody - BSA Free [NBP1-91258] -

Western Blot: Fibronectin Antibody - BSA Free [NBP1-91258] - EMT in cancer cells is regulated by m6A levels of mRNAs. a HeLa & HepG2 cells were treated with or without 10 ng/ml TGF-beta for 3 days, the m6A/A ratio of the total mRNA were determined by LC–MS/MS. b Wound healing of wild-type (control) or Mettl3Mut/− cells was recorded (left) & quantitatively analyzed (right). c Wild-type or Mettl3Mut/− cells were allowed to invade for 24 h & tested by CytoSelect™ 24-well Cell Invasion assay kits (8 µm, colorimetric format); d, e mRNA (d) & protein (e) expressions of MMP2, FN, & E-Cad in wild-type & Mettl3Mut/− HeLa cells were measured by qRT-PCR & western blot analysis, respectively. f HeLa cells were transfected with pcDNA/ALKBH5 or a vector control for 48 h, protein expression was determined by western blot analysis (left) & quantitatively analyzed (right). g Wild-type or Mettl3Mut/− cells were treated with or without 10 ng/ml TGF-beta for 3 days, protein expression was determined by western blot analysis (left) & quantitatively analyzed (right). h The expression of METTL3 in liver cancer & its matched adjacent normal tissues of 50 patients from TCGA database. i Correlation between METTL3 & CDH1 in liver cancer patients (n = 364) from TCGA database. j HeLa cells were pretreated with or without Smad2/3 inhibitor SB431542 (10 μM) & then further treated with 10 ng/ml TGF-beta for 3 days, the m6A/A ratio of the total mRNA were determined by LC–MS/MS. Data are presented as means ± SD from three independent experiments. *p < 0.05, **p < 0.01, NS, no significant, by Student’s t test. Red bar = 200 μm Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31061416), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Fibronectin Antibody - BSA Free [NBP1-91258] -

Western Blot: Fibronectin Antibody - BSA Free [NBP1-91258] - EMT in cancer cells is regulated by m6A levels of mRNAs. a HeLa & HepG2 cells were treated with or without 10 ng/ml TGF-beta for 3 days, the m6A/A ratio of the total mRNA were determined by LC–MS/MS. b Wound healing of wild-type (control) or Mettl3Mut/− cells was recorded (left) & quantitatively analyzed (right). c Wild-type or Mettl3Mut/− cells were allowed to invade for 24 h & tested by CytoSelect™ 24-well Cell Invasion assay kits (8 µm, colorimetric format); d, e mRNA (d) & protein (e) expressions of MMP2, FN, & E-Cad in wild-type & Mettl3Mut/− HeLa cells were measured by qRT-PCR & western blot analysis, respectively. f HeLa cells were transfected with pcDNA/ALKBH5 or a vector control for 48 h, protein expression was determined by western blot analysis (left) & quantitatively analyzed (right). g Wild-type or Mettl3Mut/− cells were treated with or without 10 ng/ml TGF-beta for 3 days, protein expression was determined by western blot analysis (left) & quantitatively analyzed (right). h The expression of METTL3 in liver cancer & its matched adjacent normal tissues of 50 patients from TCGA database. i Correlation between METTL3 & CDH1 in liver cancer patients (n = 364) from TCGA database. j HeLa cells were pretreated with or without Smad2/3 inhibitor SB431542 (10 μM) & then further treated with 10 ng/ml TGF-beta for 3 days, the m6A/A ratio of the total mRNA were determined by LC–MS/MS. Data are presented as means ± SD from three independent experiments. *p < 0.05, **p < 0.01, NS, no significant, by Student’s t test. Red bar = 200 μm Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31061416), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Fibronectin Antibody - BSA Free [NBP1-91258] -

Western Blot: Fibronectin Antibody - BSA Free [NBP1-91258] - Snail is involved in m6A-regulated EMT in cancer cells. a Overlapping of 2.0-fold m6A expression changes in EMT cells & EMT-related functional genes. b m6A peaks were enriched in CDS & 3′UTRs of SNAI1 genes from m6A RIP-seq data. Squares marked increases of m6A peaks in cancer cells undergoing EMT; c m6A RIP-qPCR analysis of SNAI1 mRNA in the control & EMT undergoing HeLa cells. d Protein expression of Snail in Mettl3Mut/− or AKLBH5 transfected (24 h) HeLa cells & the control. e The wound healing of wild-type or Mettl3Mut/− HeLa cells transfected with or without pcDNA/Snail for 48 h were recorded (left) & quantitatively analyzed (right). f Wild-type or Mettl3Mut/− HeLa cells were transfected with or without pcDNA/Snail for 48 h, expression of Snail, FN & E-Cad were measured by western blot analysis. Data are presented as means ± SD from three independent experiments. *p < 0.05, NS, no significant, by Student’s t test. Red bar = 200μm Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31061416), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Fibronectin Antibody - BSA Free [NBP1-91258] -

Western Blot: Fibronectin Antibody - BSA Free [NBP1-91258] - EMT in cancer cells is regulated by m6A levels of mRNAs. a HeLa & HepG2 cells were treated with or without 10 ng/ml TGF-beta for 3 days, the m6A/A ratio of the total mRNA were determined by LC–MS/MS. b Wound healing of wild-type (control) or Mettl3Mut/− cells was recorded (left) & quantitatively analyzed (right). c Wild-type or Mettl3Mut/− cells were allowed to invade for 24 h & tested by CytoSelect™ 24-well Cell Invasion assay kits (8 µm, colorimetric format); d, e mRNA (d) & protein (e) expressions of MMP2, FN, & E-Cad in wild-type & Mettl3Mut/− HeLa cells were measured by qRT-PCR & western blot analysis, respectively. f HeLa cells were transfected with pcDNA/ALKBH5 or a vector control for 48 h, protein expression was determined by western blot analysis (left) & quantitatively analyzed (right). g Wild-type or Mettl3Mut/− cells were treated with or without 10 ng/ml TGF-beta for 3 days, protein expression was determined by western blot analysis (left) & quantitatively analyzed (right). h The expression of METTL3 in liver cancer & its matched adjacent normal tissues of 50 patients from TCGA database. i Correlation between METTL3 & CDH1 in liver cancer patients (n = 364) from TCGA database. j HeLa cells were pretreated with or without Smad2/3 inhibitor SB431542 (10 μM) & then further treated with 10 ng/ml TGF-beta for 3 days, the m6A/A ratio of the total mRNA were determined by LC–MS/MS. Data are presented as means ± SD from three independent experiments. *p < 0.05, **p < 0.01, NS, no significant, by Student’s t test. Red bar = 200 μm Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31061416), licensed under a CC-BY license. Not internally tested by Novus Biologicals.